Publication
Budesonide Reverses Lung Hyperinflation in Childhood Asthma: a Controlled Study
| dc.contributor.author | Neuparth, N | |
| dc.contributor.author | Gamboa, T | |
| dc.contributor.author | Pereira, C | |
| dc.contributor.author | Rosado-Pinto, J | |
| dc.contributor.author | Rendas, A | |
| dc.date.accessioned | 2014-03-05T16:15:02Z | |
| dc.date.available | 2014-03-05T16:15:02Z | |
| dc.date.issued | 1999 | |
| dc.description.abstract | Budesonide (800 mg bid, for 2 months) was administered to 12 asthmatic children (mean age, 11.293.3 years) with lung hyperinflation (TGV]130% predicted and:or RV]140% predicted) in a randomised, placebo controlled, double blind, crossover study. Body plethysmography (panting frequency controlled at 1·s 1) was performed at the beginning, 2 months afterwards (before crossover) and at the end of the study. Budesonide significantly reduced TGV (2.3590.90 l BTPS or 126924% predicted) compared with placebo (2.5491.08 l BTPS, P 0.014 or 140921% predicted, PB0.05). In addition, budesonide significantly increased mean specific conductance (0.0690.02 cm H2O 1 l s 1 to 0.0790.01 cm H2O 1 l s 1, PB0.05). It was concluded that budesonide reduced lung hyperinflation most likely by decreasing airway inflammation. | por |
| dc.identifier.citation | Pathophysiology. 1999; 6:199–204 | por |
| dc.identifier.uri | http://hdl.handle.net/10400.17/1699 | |
| dc.language.iso | eng | por |
| dc.publisher | Elsevier | por |
| dc.subject | Asma | por |
| dc.subject | Broncopatias | por |
| dc.subject | Budesonida | por |
| dc.subject | Criança | por |
| dc.subject | HDE ALER | por |
| dc.title | Budesonide Reverses Lung Hyperinflation in Childhood Asthma: a Controlled Study | por |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 204 | por |
| oaire.citation.startPage | 199 | por |
| oaire.citation.volume | 6 | por |
| rcaap.rights | openAccess | por |
| rcaap.type | article | por |